Table 1.
Demographic characteristics of 38 patients with non-CNS EMD identifiable by FDG PET/CT imaging at presentation to our institution
| Characteristic | Value |
|---|---|
| Age at initial diagnosis, median (range), y | 11.5 (2.5-27.4) |
| Age at presentation to our institution, median (range), y | 18.6 (4.7-30.7) |
| Sex, n (%) | |
| Male | 27 (71.1) |
| Female | 11 (28.9) |
| EMD at initial diagnosis, n (%) | |
| CNS EMD | 3 (7.8) |
| Non-CNS EMD | 5 (13.2) |
| Combined CNS/non-CNS EMD | 2 (5.3) |
| Unknown | 28 (68.4) |
| Prior number of lines of therapy, median (range) | 5 (2-9) |
| Prior HSCT (n = 27), n (%) | |
| 1 | 22 (60.5) |
| >1 | 5 (13.2) |
| Prior immunotherapy (n = 23), n (%) | |
| Prior blinatumomab | 16 (42.1) |
| Prior inotuzumab | 7 (18.4) |
| Prior CAR T-cell therapy (n = 13), n (%) | |
| Prior anti–CD19 CAR | 12 (31.6) |
| Prior anti–CD22 CAR | 1 (2.6) |
| Medullary disease at presentation, n (%) * | |
| MRD-negative | 5 (13.2) |
| Low burden | 13 (34.2) |
| High burden | 20 (52.6) |
| CNS status at presentation, n (%) † | |
| CNS1/CNS2 | 35 (92.1) |
| CNS3 | 3 (7.9) |
| Non-CNS EMD at presentation, n (%) | |
| Single site | 12 (31.6) |
| Multiple sites | 26 (68.4) |
| Indication for FDG PET/CT imaging, n (%) | |
| Documented history of non-CNS EMD | 23 (60.5) |
| Incidental finding on other imaging | 8 (21.1) |
| Abnormal physical examination | 4 (10.5) |
| Isolated CNS relapse with suspected non-CNS EMD | 3 (7.9) |
*
MRD-negative indicates no disease detectable by flow cytometry. Low burden includes M1 marrow (<5% blasts); high burden indicates M2 (5%-25% blasts) and M3 (>25% blasts) marrow.
†
CNS1 indicates 0 blasts detectable on cytospin; CNS2, white blood cell counts <5/μL, cytospin positive for blasts; and CNS3, white blood cell counts ≥5 μL, cytospin positive for blasts.